Status: Recruiting
A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies
This modular, multi-part, multi-arm, Phase 1/2, FIH study allows the evaluation of the safety and tolerability of CT7439, dosed as a monotherapy and in combination with anticancer treatment in participants with solid malignancies.
Participants needed: 50
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Carrick Therapeutics LimitedUpdated: Nov 3, 2025Locations: 6
Eligibility criteria
Histopathologically or cytologically confirmed diagnosis of malignant disease ev... [+6]
Prior therapy with a specific CDK12/13 inhibitor, within any timeframe prior to... [+17]